Kiniksa Pharmaceuticals International (KNSA) Q4 2025 earnings summary

Executive summary

• Achieved ARCALYST net product revenue of $202.1M in Q4 2025 and $677.6M for full year 2025, up 62% year-over-year, positioning for continued growth in 2026 and beyond.

• Net income reached $14.2M in Q4 2025 and $59.0M for full year 2025, reversing prior year losses.

• Maintained strong financial position with $414.1M in cash as of year-end 2025, with no debt.

• Advanced pipeline with ongoing phase II/III trials for KPL-387 (Orphan Drug Designation) and plans to initiate clinical studies for KPL-1161 by end of 2026.

• 2026 ARCALYST revenue projected at $900–$920M.

Financial highlights

• Q4 2025 product revenue was $202.1M, up from $122.5M in Q4 2024; full year revenue was $677.6M, up from $417.0M in 2024.

• Operating income for 2025 was $77.2M, compared to a loss of $45.6M in 2024.

• Net income per share for 2025 was $0.80 basic and $0.75 diluted, compared to a loss per share in 2024.

• Cash, cash equivalents, and short-term investments totaled $414.1M at year-end 2025, up from $243.6M at year-end 2024.

• Operating expenses increased due to higher cost of goods, collaboration expenses, and SG&A investments.

Outlook and guidance

• 2026 ARCALYST net product revenue expected between $900M and $920M.

• Current operating plan expected to remain cash flow positive on an annual basis.

• Phase II data for KPL-387 expected in the second half of 2026; KPL-1161 Phase 1 trial to initiate by end of 2026.

• Continued investment in value-creating opportunities supported by financial strength.